Crossmark

Clinical impact of 99mTc-MAA SPECT/CT-based personalized predictive dosimetry in selective internal radiotherapy: a real-life single-center experience in unresectable HCC patients

Crossref DOI link: https://doi.org/10.1186/s41824-023-00171-8

Published Online: 2023-07-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bucalau, Ana-Maria https://orcid.org/0000-0003-0444-7806
Collette, Benoît

Tancredi, Illario

Vouche, Michael

Pezzullo, Martina

Bouziotis, Jason

Moreno-Reyes, Rodrigo

Trotta, Nicola

Levillain, Hugo

Van Laethem, Jean Luc

Verset, Gontran
License Information

Text and Data Mining valid from 2023-07-07

Version of Record valid from 2023-07-07
More Information

Article History

Received: 9 April 2023

Accepted: 22 June 2023

First Online: 7 July 2023

Declarations

:

: Tancredi: consultant for Terumo Europe NV and Boston Scientific. G. Verset: consultant for Terumo Europe NV and Boston Scientific. Other authors have no competing interests to declare.

: Hôpital Erasme Ethics Committee P2021/221.

: Not applicable.

Document is current

Any future updates will be listed below